

Potential new drug target in Lou Gehrig's disease

14 November 2011

Two proteins conspire to promote a lethal neurological disease, according to a study published online this week in the *Journal of Experimental Medicine*.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating neurodegenerative disorder that results in progressive loss of motor function and ultimately death. More than 90% of ALS cases have no known genetic cause or family history. However, in some patients, spinal cord cells contain unusual accumulations of a protein called TDP-43.

Jean-Pierre Julien and colleagues at Laval University in Quebec now find that TDP-43 binds to an [inflammatory protein](#) called NF-κB p65 in the spinal cords of ALS patients but not of healthy individuals. TDP-43 and p65 were also more abundant in ALS than healthy spinal cords. In [spinal cord cells](#) called microglia, TDP-43 and p65 cooperated to ramp up production of factors capable of promoting inflammation and killing nearby neurons. In a mouse model of ALS, treatment with an agent capable of blocking p65 activity minimized neuron loss and eased disease symptoms.

These findings highlight p65 as a potential [therapeutic target](#) for this debilitating disorder.

More information: Swarup, V., et al. 2011. J. Exp. Med. [doi:10.1084/jem.20111313](https://doi.org/10.1084/jem.20111313)

Provided by Rockefeller University Press

APA citation: Potential new drug target in Lou Gehrig's disease (2011, November 14) retrieved 6 May 2021 from <https://medicalxpress.com/news/2011-11-potential-drug-lou-gehrig-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.